- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02737657
An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan (CRATOS)
November 14, 2016 updated by: Janssen-Cilag International NV
Observational, Prospective, Parallel Cohort Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea on a Background Therapy of Metformin With or Without a DPP-4 Inhibitor During Ramadan Fasting in Patients With Type 2 Diabetes
The primary purpose of this study is to describe the tolerability of canagliflozin and any sulphonylurea (each administered with metformin with or without a DPP-4 inhibitor), in terms of the percentage of patients with at least one episode of hypoglycaemia, in patients with T2DM who fast during Ramadan.
Study Overview
Status
Completed
Conditions
Detailed Description
This is non-randomized, parallel-cohort, prospective, multicenter (when more than one hospital works on a medical research study), observational study to describe the treatment of T2DM with canagliflozin during the Holy Month of Ramadan.
Observed participants will be participants with T2DM (at the time of enrollment) who are being treated with either canagliflozin or any sulphonylurea, each administered on a background therapy of metformin with or without a DPP-4 inhibitor within clinical practice, and who intend to fast during the Ramadan period.
On enrollment, patients will enter one of two parallel treatment cohorts based on their ongoing T2DM therapy: canagliflozin and metformin with or without a DPP-4 inhibitor will be the treatment of interest, while any sulphonylurea and metformin with or without a DPP-4 inhibitor will serve as the reference standard treatment.
Safety will be monitored throughout the study.
Study Type
Observational
Enrollment (Actual)
379
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kuwait City, Kuwait
-
-
-
-
-
Amioun, Lebanon
-
Beirut, Lebanon
-
Nabatieh, Lebanon
-
Saida, Lebanon
-
Taalabya, Lebanon
-
Tripoli, Lebanon
-
-
-
-
-
Al Ain, United Arab Emirates
-
Dubai, United Arab Emirates
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Participants with a confirmed diagnosis of type 2 diabetes and has been treated with canagliflozin or any sulphonylurea, each on a background therapy of metformin with or without a DPP-4 inhibitor, will be enrolled in this study.
Description
Inclusion Criteria:
- Participants who has a confirmed diagnosis of type 2 diabetes for more than 12 months before enrollment
- Participants who has been treated with canagliflozin or any sulphonylurea, each on a background therapy of metformin with or without a dipeptidyl peptidase 4 (DPP-4) inhibitor, for >12 weeks before enrollment
- Participants Intends to fast during Ramadan in 2016
- Participants Will be able to continue on the products under study (i.e., canagliflozin or any sulphonylurea, each with metformin with or without a DPP-4 inhibitor) through the Ramadan period, as judged by the participating physician
- Participants who has a glycated hemoglobin (HbA1c) measurement less than and equal to (<=) 8.5% within 8 weeks before the start of Ramadan.
Exclusion Criteria:
- Participant is being treated with insulin and/or any type 2 diabetes mellitus (T2DM) therapy other than canagliflozin, any sulphonylurea, and metformin with or without a DPP 4 inhibitor, or has changed their T2DM therapy within 12 weeks before enrollment (dose changes of canagliflozin, a sulphonylurea, metformin, and a DPP 4 inhibitor where applicable are accepted)
- Participant is currently being treated with loop diuretics
- Participants who has a history of severe hypoglycaemia events within the 6 months prior to enrollment (defined as a hypoglycaemia event for which the patient required assistance from another person, or which resulted in seizure or loss of consciousness).
- Participants who has heart failure (NYHA 3-4) or advanced cardiovascular disease.
- Participants who has an estimated glomerular filtration rate (eGFR) less than (<) 60 milliliter/minute (mL/min)/1.73 m^2.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Cohort 1
Participants who are already receiving Canagliflozin and Metformin with or without a DPP-4 inhibitor daily during Ramadan period will be observed as the part of study.
|
Cohort 2
Participants who are already receiving any sulphonylurea and Metformin with or without a DPP-4 inhibitor daily during Ramadan period will be observed as a part of study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With at Least one Episode of Hypoglycaemia
Time Frame: during the Ramadan period (up to 1 month)
|
Hypoglycaemia events are defined by symptoms (e.g., dizziness, visual blurring, palpitations, nausea, sweating, confusion, tremor or intense hunger) reported by the patient in the patient diary, with confirmation by a physician where applicable; Episode may be documented via a self-monitored blood glucose measurement <70 milligram/deciliter (mg/dl).
|
during the Ramadan period (up to 1 month)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Volume Depletion Events
Time Frame: during the Ramadan period (up to 1 month)
|
during the Ramadan period (up to 1 month)
|
|
Treatment Adherence Based on the Percentage of Prescribed Doses of Canagliflozin or Sulphonylurea Taken by Participants
Time Frame: during the Ramadan period (up to 1 month)
|
during the Ramadan period (up to 1 month)
|
|
Time to the First Hypoglycaemia Event
Time Frame: during the Ramadan period (up to 1 month)
|
during the Ramadan period (up to 1 month)
|
|
Relationship of Hypoglycaemia Events With Clinical Parameters
Time Frame: during the Ramadan period (up to 1 month)
|
Precipitating factors, symptoms and blood glucose concentration during hypoglycaemia episode will be described.
|
during the Ramadan period (up to 1 month)
|
Relationship of Hypoglycaemia Events With Used Treatment
Time Frame: during the Ramadan period (up to 1 month)
|
Causal relationship of hypoglycaemia event to treatment will be evaluated.
|
during the Ramadan period (up to 1 month)
|
Relationship of Hypoglycaemia Events With Treatment Adherence
Time Frame: during the Ramadan period (up to 1 month)
|
Treatment adherence will be based on the percentage of prescribed doses of canagliflozin or sulphonylurea that are missed during the Ramadan period, as reported in the patient diary.
Any changes in study medication (i.e.
missed or delayed dosing) due to hypoglycaemia events will be captured.
|
during the Ramadan period (up to 1 month)
|
Relationship of Hypoglycaemia Events With Number of Fasting Days
Time Frame: during the Ramadan period (up to 1 month)
|
Number of days when fasting was broken due to hypoglycaemia or hypoglycaemia prevention will be captured.
|
during the Ramadan period (up to 1 month)
|
Relationship of Volume Depletion Events With Clinical Parameters
Time Frame: during the Ramadan period (up to 1 month)
|
Precipitating factors, symptoms and blood glucose concentration during volume depletion related adverse events will be described.
|
during the Ramadan period (up to 1 month)
|
Relationship of Volume Depletion Events With Used Treatment
Time Frame: during the Ramadan period (up to 1 month)
|
Causal relationship of volume depletion related adverse event to treatment will be evaluated.
|
during the Ramadan period (up to 1 month)
|
Relationship of Volume Depletion Events With Treatment Adherence
Time Frame: during the Ramadan period (up to 1 month)
|
Treatment adherence will be based on the percentage of prescribed doses of canagliflozin or sulphonylurea that are missed during the Ramadan period, as reported in the patient diary.
Any changes in study medication (i.e.
missed or delayed dosing) due to Volume depletion related adverse events will be captured.
|
during the Ramadan period (up to 1 month)
|
Relationship of Volume Depletion Events With Number of Fasting Days
Time Frame: during the Ramadan period (up to 1 month)
|
Number of days when fasting was broken due to the volume depletion related adverse event will be reported.
|
during the Ramadan period (up to 1 month)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2016
Primary Completion (Actual)
September 1, 2016
Study Completion (Actual)
September 1, 2016
Study Registration Dates
First Submitted
March 23, 2016
First Submitted That Met QC Criteria
April 8, 2016
First Posted (Estimate)
April 14, 2016
Study Record Updates
Last Update Posted (Estimate)
November 15, 2016
Last Update Submitted That Met QC Criteria
November 14, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR108100
- 28431754DIA4016 (Other Identifier: Janssen-Cilag International)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China